Brief: Updated Results From The Phase 1/2 Study Of Essa's Lead Candidate Epi-7386 In Combination With Enzalutamide Highlighted At The 29Th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma

26/10/2022 12:05

Oct 26 (Reuters) - ESSA Pharma Inc  EPIX.O :
    * UPDATED RESULTS FROM THE PHASE 1/2 STUDY OF ESSA'S LEAD
CANDIDATE EPI-7386 IN COMBINATION WITH ENZALUTAMIDE HIGHLIGHTED
AT THE 29TH ANNUAL PROSTATE CANCER FOUNDATION SCIENTIFIC RETREAT
    * ESSA PHARMA INC - EPI-7386 IN COMBINATION WITH
ENZALUTAMIDE WAS
SAFE AND WELL-TOLERATED AT DOSES TESTED WITH CLINICALLY RELEVANT
DRUG EXPOSURES
    * ESSA PHARMA INC - DEEP AND DURABLE PROSTATE SPECIFIC
ANTIGEN
("PSA") REDUCTIONS OBSERVED IN FIVE OF SIX PATIENTS

Source text for Eikon:  ID:nPn6dc8q0a 
Further company coverage:  EPIX.O 
 ((Reuters.Briefs@thomsonreuters.com;))